BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2015
No trial phase data available
No trial data available
No trial data available
No approval data available
- Oral infigratinib produced favorable trends versus placebo on exploratory endpoints including sleep apnea, otitis media and body composition at 52 weeks in the Phase 3 PROPEL 3 trial. - Mean total apnea-hypopnea index rose 10.4% with infigratinib versus 49.2% with placebo, and was unchanged in children younger than 8 years. - Annualized otitis media event rates were 38% lower overall and 47% lower in children under 8 years compared with placebo. - BridgeBio has submitted an NDA to the FDA for achondroplasia and anticipates a U.S. launch in mid-2027, with an EMA filing planned for Q4 2026.
- BioMarin and Ascendis Pharma resolved all pending patent disputes, with Ascendis agreeing to pay royalties on sales of its achondroplasia drug Yuviwel (navepegritide). - Ascendis will pay BioMarin 20% of Yuviwel net sales in the U.S. and 18% in the EU, Brazil, and South Korea through May 2030. - The license covers all current and potential indications, including achondroplasia and hypochondroplasia, and use in combination with other medicines. - The settlement recognizes BioMarin's pioneering C-type natriuretic peptide (CNP) technology, including its development of VOXZOGO (vosoritide).
- Advocates living with limb-girdle muscular dystrophy from more than 20 states held over 60 congressional meetings during The Speak Foundation's LGMD Day on the Hill. - The community is pressing for federal research investment, expanded Department of Defense funding access, and clearer regulatory pathways for rare-disease treatments. - Momentum is building around what could be the first FDA-approved LGMD therapy, a treatment for the LGMD 2I/R9 subtype developed by BridgeBio. - The Speak Foundation honored Reps. John Joyce and Jake Auchincloss with its 2026 Congressional Champion for Limb-Girdle Muscular Dystrophy Awards.
- BridgeBio Pharma secured a $1 billion preferred equity raise, strengthening its financial position to advance key drug candidates through clinical and regulatory milestones. - The company reported robust revenue growth with 2025 revenue reaching $502.08 million, though it remains unprofitable with a net income margin of -124.41%. - Analyst consensus remains strongly bullish with a consensus price target of $102.75, implying significant upside from the current trading price of $77.91. - Ongoing cash burn and consistent earnings misses present substantial risks that require careful monitoring of upcoming clinical and regulatory catalysts.
- Pfizer reached settlements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla to extend tafamidis patent protection through June 1, 2031, preventing generic competition until early next decade. - The agreements ensure U.S. revenues for Vyndamax, which generated nearly $6.4 billion worldwide last year, will remain relatively stable from 2028 through mid-2031 instead of facing significant decline. - Tafamidis is the market-leading treatment for transthyretin-mediated amyloidosis cardiomyopathy, a rare heart disease that has proven to be a much larger commercial opportunity than previously anticipated. - The patent extension impacts the competitive landscape for other companies developing treatments for the same condition, including BridgeBio Pharma's Attruby and Alnylam Pharmaceuticals' Amvuttra.
- BridgeBio's PROPEL 3 trial met its primary endpoint, showing oral infigratinib significantly improved annualized height velocity by 1.74 cm/year compared to placebo in children with achondroplasia. - The study achieved the first statistically significant improvement in body proportionality for any achondroplasia therapy, with a meaningful reduction in upper-to-lower body ratio in children under 8 years. - Infigratinib demonstrated excellent safety with no drug-related discontinuations or serious adverse events, positioning it as the first oral FGFR3-targeted therapy for this genetic condition. - BridgeBio plans regulatory submissions in the second half of 2026 and will accelerate development for hypochondroplasia based on these breakthrough results.
- BridgeBio's oral drug infigratinib demonstrated superior growth acceleration in children with achondroplasia, achieving 1.74-2.1 cm per year improvement over placebo in a pivotal trial of over 100 patients. - The drug showed best-in-indication efficacy compared to existing injectable treatments, with BioMarin's Voxzogo showing 1.57 cm per year and Ascendis' therapy showing 1.49-1.78 cm per year in their respective trials. - Infigratinib was well-tolerated with no serious adverse events or treatment discontinuations due to side effects, positioning it as a convenient oral alternative to current daily injection therapies. - BridgeBio plans to submit marketing applications in the second half of 2026 and accelerate development in hypochondroplasia, potentially capturing significant market share in the growing dwarfism treatment space.
- The FDA has lifted a clinical hold on Intellia Therapeutics' late-stage trial testing nexiguran ziclumeran, a CRISPR-based gene therapy for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). - The clinical hold was imposed in October after a patient developed severe liver-related side effects, but Intellia has since agreed to stronger safety monitoring measures. - A separate trial testing the same therapy for the cardiac form of the disease remains on hold following a patient death in November. - The company has expanded the nerve disease trial enrollment from 50 to 60 patients and plans to restart patient enrollment immediately.
- BridgeBio Pharma is developing BBP-418 for muscular dystrophy, which could become the first-ever approved treatment for LGMD2I/R9 by fall 2025. - The company's pipeline includes Encaleret for a rare calcium disorder with no approved drug and Infigratinib as a potential first oral therapy for achondroplasia, the most common form of dwarfism. - Analysts project BridgeBio's revenue to increase by 122% in 2025 to $493.4 million, with the company maintaining $756.9 million in cash to fund ongoing Phase 3 trials and product launches.
- BridgeBio's Phase 3 FORTIFY study of BBP-418 met all primary and secondary endpoints in patients with limb-girdle muscular dystrophy type 2I/R9, showing significant improvements in muscle function and biomarkers. - The investigational oral therapy demonstrated a 1.8-fold increase in glycosylated alpha-dystroglycan and an 82% reduction in muscle damage markers compared to placebo at 12 months. - Patients treated with BBP-418 showed clinically meaningful improvements in walking speed and lung function, with the company planning to file for FDA approval in the first half of 2026. - The positive results represent a potential breakthrough for LGMD2I/R9, a progressive genetic disorder that currently has no approved treatments and leads to loss of mobility and respiratory complications.
